KCIA
MTNB icon

Kingsbury Capital Investment Advisors’s Matinas BioPharma MTNB Stock Holding History

Kingsbury Capital Investment Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$76K Hold
2,399
– – 0.12% 73
2022
Q2 		$95K Hold
2,399
– – 0.13% 83
2022
Q1 		$96K Buy
+2,399
New +$88.3K 0.11% 87

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Kingsbury Capital Investment Advisors's MTNB Position: Q3 2022 in Review

Kingsbury Capital Investment Advisors held its Matinas BioPharma (MTNB) position steady in Q3 2022 at 2,399 shares worth $76K. The position accounts for 0.12% of the portfolio, ranked #73.

Kingsbury Capital Investment Advisors first reported a position in MTNB in Q1 2022 and has held it in 3 quarters since. The position peaked at $96K in Q1 2022. 55 funds tracked by Wall St. Rank hold MTNB as of Q3 2022.

  • Kingsbury Capital Investment Advisors held 2,399 shares of Matinas BioPharma worth $76K as of Q3 2022.
  • Kingsbury Capital Investment Advisors left its Matinas BioPharma share count unchanged in Q3 2022.
  • Matinas BioPharma made up 0.12% of Kingsbury Capital Investment Advisors's portfolio in Q3 2022, its #73 holding.
  • Kingsbury Capital Investment Advisors first reported a position in Matinas BioPharma in Q1 2022 and has held it in 3 quarters since.
  • Kingsbury Capital Investment Advisors's Matinas BioPharma position peaked at $96K in Q1 2022.
  • 55 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2022.

Based on Kingsbury Capital Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.